Literature DB >> 16597603

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.

Niels W C J van de Donk, Nicolaus Kröger, Ute Hegenbart, Paolo Corradini, Jesus F San Miguel, Hartmut Goldschmidt, Jose A Perez-Simon, Mark Zijlmans, Reinier A Raymakers, Vittorio Montefusco, Francis A Ayuk, Marinus H J van Oers, Arnon Nagler, Leo F Verdonck, Henk M Lokhorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16597603     DOI： 10.1182/blood-2005-11-4449

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  18 in total

1.  Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

Authors:  Junya Kuroda; Tsutomu Kobayashi; Yasuhiko Tsutsumi; Mio Yamamoto; Muneo Ohshiro; Nana Sasaki; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Miki Kiyota; Ryuko Nakayama; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-10-27       Impact factor: 2.490

2.  Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Authors:  Luisa Giaccone; Barry Storer; Francesca Patriarca; Marcello Rotta; Roberto Sorasio; Bernardino Allione; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Paola Omedè; Sara Bringhen; Massimo Aglietta; Alessandro Levis; Nicola Mordini; Andrea Gallamini; Renato Fanin; Massimo Massaia; Antonio Palumbo; Giovannino Ciccone; Rainer Storb; Ted A Gooley; Mario Boccadoro; Benedetto Bruno
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

3.  Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  Claire Fabre; Serge Koscielny; Mohamad Mohty; Nathalie Fegueux; Didier Blaise; Natacha Maillard; Reza Tabrizi; Mauricette Michallet; Gérard Socié; Ibrahim Yakoub-Agha; Frédéric Garban; Madalina Uzunov; Sylvie François; Nathalie Contentin; Simona Lapusan; Jean-Henri Bourhis
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 4.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.

Authors:  Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-24       Impact factor: 5.742

5.  Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.

Authors:  Tereza Coman; Emmanuel Bachy; Mauricette Michallet; Gérard Socié; Madalina Uzunov; Jean Henri Bourhis; Simona Lapusan; Alain Brebion; Stéphane Vigouroux; Sébastien Maury; Sylvie François; Anne Huynh; Bruno Lioure; Ibrahim Yakoub-Agha; Olivier Hermine; Noël Milpied; Mohamad Mohty; Marie Thérèse Rubio
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

6.  Treatment of pediatric refractory Crohn's disease with thalidomide.

Authors:  Cui-Fang Zheng; Jia-Hua Xu; Ying Huang; Ying-Kit Leung
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

7.  Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

Authors:  George E Georges; Michael B Maris; David G Maloney; Brenda M Sandmaier; Mohamed L Sorror; Judith A Shizuru; Thoralf Lange; Edward D Agura; Benedetto Bruno; Peter A McSweeney; Michael A Pulsipher; Thomas R Chauncey; Marco Mielcarek; Barry E Storer; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-01       Impact factor: 5.742

Review 8.  Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.

Authors:  John Koreth; Edwin P Alyea; William J Murphy; Lisbeth A Welniak
Journal:  Biol Blood Marrow Transplant       Date:  2009-12       Impact factor: 5.742

9.  A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.

Authors:  David H Vesole; Lijun Zhang; Neal Flomenberg; Philip R Greipp; Hillard M Lazarus; Carol A Huff
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

10.  A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.

Authors:  Alex F Herrera; Haesook T Kim; Bhavjot Bindra; Kyle T Jones; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Sarah Nikiforow; Bruce R Blazar; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.